The strong efficacy and CNS activity data de-risk silevertinib's pivotal path; the upcoming FDA meeting and ASCO presentation on May 30 are key catalysts. Traders should watch for updates on the pivotal trial design and potential partnership interest, as well as the randomized Phase 2 GBM trial initiation.
Price Chart
Executive Summary
Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC with EGFR non-classical mutations, showing a preliminary median PFS of 15.2 months, 60% ORR, and 86% CNS ORR with no new brain metastases. The company plans to meet with the FDA later this year to discuss a pivotal development plan, positioning silevertinib as a potential practice-changing therapy for an underserved patient population.
Key Facts
- Preliminary median PFS of 15.2 months in 43 patients with 1L NSCLC and EGFR-NCMs
- ORR of 60% and DCR of 91% by RECIST 1.1
- 86% CNS ORR in patients with measurable brain metastases; no patients developed de novo brain metastases
- Median DOR not yet reached; 53% of patients remain on therapy (longest at 23.5 months)
- No new safety signals; TRAEs > Grade 3 reduced to 28% after dose reduction
- Company plans to meet with FDA later this year to discuss pivotal development plan
- Data to be presented at ASCO 2026 on May 30
Financial Impact
Positive Phase 2 data for silevertinib in a large addressable market (EGFR-NCM NSCLC) with potential to become standard of care; no financial figures provided in the release.
Risk Factors
- Phase 2 data is preliminary with small sample size (n=43) and median follow-up of only 11.2 months
- FDA meeting outcome and pivotal trial design are uncertain
- Competition from other EGFR TKIs (e.g., osimertinib, amivantamab) in the NCM space
- Clinical-stage company with no approved products; reliance on successful development and regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299802 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $2.05 $2.06 | ▲ +0.49% | ▲ +1.16% | $1.69 (−17.56%) |
Aug 5, 2026 11w ago | 8-K | $1.92 $1.95 | ▲ +1.56% | ▲ +0.95% | $1.69 (−11.98%) |
May 21, 2026 22w ago | 8-K | $2.28 $2.33 | ▲ +2.19% | ▲ +1.61% | $1.69 (−25.88%) |
May 21, 2026 22w ago | Press Release | $2.28 $2.33 | ▲ +2.19% | ▲ +1.61% | $1.69 (−25.88%) |
May 7, 2026 24w ago | 8-K | $2.72 $2.99 | ▲ +9.93% | ▲ +9.10% | $1.69 (−37.87%) |
Apr 21, 2026 26w ago | Press Release | $3.15 $3.35 | ▲ +6.35% | ▲ +5.33% | $1.69 (−46.35%) |
Mar 16, 2026 32w ago | Press Release | $2.23 $2.17 | ▼ −2.69% | ▼ −1.29% | $1.69 (−24.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers